682 Trial in progress: phase 1 trial of TSC-100 and TSC-101, engineered T-cell therapies targeting minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation

Malki, M. A., Keyzner, A., Suh, H. C., Matin, A., Buonomo, E., Wang, Y., Abelowitz, N., Murray, J., MacBeath, G., Barton, D., Chattopadhyay, S., & Reshef, R. (2023). 682 Trial in progress: phase 1 trial of TSC-100 and TSC-101, engineered T-cell therapies targeting minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0682
Authors:
Monzr M. Al Malki
Alla Keyzner
Hyung Chan Suh
Aasiya Matin
Erica L. Buonomo
Yun Wang
Nina Abelowitz
J. A. H. Murray
Gavin MacBeath
Débora Barton
Shrikanta Chattopadhyay
Ran Reshef
Affiliated Authors:
Ran Reshef
Publication Type:
Article
Unique ID:
10.1136/jitc-2023-sitc2023.0682
Publication Date:
Data Source:
OpenAlex

Record Created: